A detailed history of Steward Partners Investment Advisory, LLC transactions in Cel Sci Corp stock. As of the latest transaction made, Steward Partners Investment Advisory, LLC holds 9,600 shares of CVM stock, worth $6,336. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,600
Previous 9,600 -0.0%
Holding current value
$6,336
Previous $11,000 9.09%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.63 - $3.08 $3 - $6
-2 Reduced 0.02%
9,600 $18,000
Q3 2023

Nov 13, 2023

BUY
$1.17 - $2.86 $1,172 - $2,865
1,002 Added 11.65%
9,602 $12,000
Q2 2023

Aug 14, 2023

BUY
$2.11 - $2.83 $6,541 - $8,773
3,100 Added 56.36%
8,600 $20,000
Q4 2022

Feb 15, 2023

SELL
$1.99 - $3.52 $6,766 - $11,968
-3,400 Reduced 38.2%
5,500 $12,000
Q3 2022

Nov 10, 2022

BUY
$3.09 - $5.23 $7,725 - $13,075
2,500 Added 39.06%
8,900 $28,000
Q1 2022

May 02, 2022

BUY
$3.93 - $7.7 $7,860 - $15,400
2,000 Added 45.45%
6,400 $25,000
Q4 2021

Feb 08, 2022

SELL
$7.1 - $12.82 $11,360 - $20,512
-1,600 Reduced 26.67%
4,400 $31,000
Q3 2021

Nov 12, 2021

BUY
$7.64 - $12.49 $7,640 - $12,490
1,000 Added 20.0%
6,000 $66,000
Q1 2021

May 14, 2021

SELL
$12.0 - $27.64 $108 - $248
-9 Reduced 0.18%
5,000 $76,000
Q4 2020

Feb 11, 2021

BUY
$11.05 - $16.62 $22,100 - $33,240
2,000 Added 66.47%
5,009 $58,000
Q2 2019

Jul 25, 2019

BUY
$3.77 - $8.67 $11,343 - $26,088
3,009 New
3,009 $25,000
Q4 2018

Jan 15, 2019

SELL
$2.65 - $4.26 $68 - $110
-26 Closed
0 $0
Q1 2018

Apr 20, 2018

BUY
$1.38 - $2.33 $23 - $39
17 Added 188.89%
26 $0
Q4 2017

Jan 19, 2018

BUY
$1.63 - $2.0 $14 - $18
9
9 $0

Others Institutions Holding CVM

About CEL SCI CORP


  • Ticker CVM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,367,500
  • Market Cap $28.6M
  • Description
  • CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...
More about CVM
Track This Portfolio

Track Steward Partners Investment Advisory, LLC Portfolio

Follow Steward Partners Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.